Tempus AI Inc. (NASDAQ:TEM) stock is trading higher Thursday, extending gains from the previous session.
BTIG maintained a Buy rating on Tempus AI on Thursday and raised its price forecast to $80.
Investors are also linking a major cancer trial milestone to Tempus AI’s pending $1.5 billion acquisition of Personalis Inc. Nasdaq futures are down 0.54%, while S&P 500 futures have slipped 0.33%.
Clinical Trial Milestone
Merck & Co. Inc. (NYSE:MRK) and Moderna Inc. (NASDAQ:MRNA) released Phase 3 trial results Wednesday for the INTerpath-001 study.
